• Anatara Lifesciences joins the fight against IBD

    19th May is World IBD Day and unites people worldwide in their fight against Crohn’s disease & ulcerative colitis, known as inflammatory bowel diseases (IBD). Anatara is developing an over-the-counter medicine for gastrointestinal health to help patients manage their debilitating symptoms. More >>

  • Advancing gastrointestinal health naturally

    Our Gastrointestinal ReProgramming (GaRP) over-the-counter medicine is focused on addressing the chronic symptoms associated with irritable bowel syndrome (IBS) and the inflammatory bowel diseases (IBD). More >>

  • Anatara COVID-19 Market Update

    Anatara Lifesciences provides an update on the impact to the Company of the COVID-19 pandemic.The Company remains committed to its corporate strategy and focused on delivering on its anticipated milestones during the year ahead. More>>

  • Anatara supports Antibiotic Awareness Week

    Each November, Anatara Lifesciences supports the global campaign to raise awareness of antibiotic resistance and to encourage best practices among the general public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance. More >>

  • Summary of GaRP preclinical studies

    Anatara’s Gastrointestinal ReProgramming (GaRP) product successfully completes preclinical program – provides strong scientific proof that the unique over-the-counter medicine may be the breakthrough product so desperately needed by patients suffering chronic bowel conditions. More >>

Company description

Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a specialist life sciences company with expertise in developing products for animal and human health. We are currently focused on building a pipeline of evidence-based, over-the-counter gastrointestinal health products, through in-house development and in-licencing and distribution opportunities.

Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Recent coverage



More Events


Investors Home